/

VXRT

Vaxart, Inc.Closed

0.4600+0.02 +4.55%USD

OTC Markets OTCQX · as of Oct 13, 16:00 ET · 15m delay

Open

0.4305

Prev close

0.4400

Day range

0.43000.4699

52-week range

0.31000.8400

Volume

131.43K0.47×

Mkt cap

112.10M

P/E ttm

2.71

Fwd P/E

-0.45

EPS ttm

0.1700

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−45.24%

Price Chart

Yahoo Finance · delayed

VXRTOct 13, 2026O 0.4400H 0.4700L 0.4200C 0.4600+0.0200 (+4.55%)Vol 329.10K

SMA 500.4932
SMA 2000.5890

1Y change +35.29% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VXRT Vaxart, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +4.55%
1 month: −6.12%
3 months: −16.36%
6 months: −35.21%
Year to date: +31.43%
1 year: +35.29%

Valuation & ownership

Market cap: 112.10M
Enterprise value: 59.45M
P/E (ttm): 2.71
Forward P/E: -0.45
PEG ratio: —
Price / book: 1.36
Price / sales (ttm): 0.46
EV / EBITDA: 1.30
EPS (ttm): 0.1700
EPS (forward): -1.03
Beta (5y monthly): 1.06
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 243.70M
Float: 239.25M
Short % of float: 7.51%
Short ratio (days): 1.87
Held by insiders: 1.42%
Held by institutions: 0.05%
Avg volume (3m): 281.68K
50-day average: 0.4958
200-day average: 0.5885
52-week change: +35.29%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 49.4
vs 50-day SMA: −6.73%
vs 200-day SMA: −21.90%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.33%
Realised vol (20d, ann.): 48.9%
From 52-week high: −45.24%
From 52-week low: +48.39%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

3.33

+624.64% implied

Low 2.00Median 4.00High 4.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

Buy / hold / sell counts

DES

About Vaxart, Inc.

Yahoo Finance profile

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 65
Headquarters: South San Francisco, CA, United States
Website: vaxart.com
Officers: Mr. Steven Lo President, CEO & Director
Dr. Sean N. Tucker Ph.D. Senior VP & Chief Scientific Officer
Dr. James F. Cummings M.D. Chief Medical Officer

SEAS

Seasonality · VXRT

2007–2026 · monthly returns

Strongest month Jan +26.02%Weakest month Oct −9.53%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	65.7	37.9	-23.7	26.2	-15.6	-6.2	-11.5	-5.6	-11.8	2.2			+31.4%
2025	3.0	-25.0	-19.6	7.3	-2.3	4.7	-17.8	5.4	-7.7	-8.3	12.1	-5.4	−47.0%
2024	107.0	3.4	6.6	-45.4	15.5	-18.3	0.0	29.9	-2.3	-9.4	-22.1	10.0	+15.8%
2023	12.5	-27.8	-2.6	6.6	50.6	-40.2	12.3	0.0	-8.5	-12.0	9.1	-20.8	−40.6%
2022	-21.1	2.6	-0.8	-31.0	4.6	-3.8	5.1	-15.8	-29.7	-23.4	-29.3	-18.6	−84.7%
2021	109.8	-40.3	-15.4	78.2	-38.6	13.1	-4.0	24.5	-11.2	-15.6	18.6	-21.2	+9.8%
2020	257.1	129.6	-38.3	52.5	-0.7	230.2	6.1	-36.8	12.1	-26.0	62.2	-28.4	+1531.4%
2019	9.0	-16.1	12.8	-61.9	-12.2	3.1	3.0	1.4	-48.6	-11.1	3.1	6.1	−81.4%
2018	1.8	-12.4	-5.0	-1.1	-2.5	-40.8	0.7	0.0	-6.6	2.8	5.1	-39.0	−70.0%
2017	5.7	-54.6	10.2	-7.7	-21.7	42.6	-17.9	14.5	9.5	-10.1	3.2	-10.9	−53.7%
2016	-17.0	-4.3	-2.6	6.0	-7.5	-4.8	-2.1	-2.9	44.4	-34.4	10.3	-11.5	−36.6%
2015	7.1	5.0	-8.7	-1.3	-3.1	-5.9	14.0	-8.9	-7.9	-2.5	-3.6	4.3	−13.4%
2014	19.6	32.1	-7.7	-39.6	-27.1	5.9	12.6	-28.3	7.4	-0.8	-10.2	1.8	−46.5%
2013	-1.0	1.0	1.8	3.4	-13.8	-4.7	17.4	6.2	-2.8	-8.4	10.7	-1.2	+5.0%
2012	-1.6	1.6	-1.1	-10.2	-5.4	0.0	2.5	-1.2	10.6	-3.4	-57.1	-9.3	−64.6%
2011	-3.3	1.1	2.7	-0.5	-4.8	-2.2	-63.4	-4.1	-11.1	9.5	-1.6	3.9	−67.5%
2010	-1.0	7.8	5.2	2.2	-2.8	-0.4	5.1	-15.2	-1.0	2.3	5.9	11.3	+18.2%
2009	23.3	-8.7	-1.9	-7.0	-17.7	-14.1	5.8	18.7	17.7	-9.5	52.0	-0.8	+46.3%
2008	-2.2	9.6	3.9	0.2	2.7	-4.8	36.3	7.3	-19.1	-15.9	1.8	-16.0	−7.2%
2007	-14.5	-8.6	0.2	-2.1	-1.2	-10.5	-7.4	-16.9	14.7	-4.9	-14.5	9.4	−46.8%

INSD

Insider Activity · VXRT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 15, 2026	Finney KevinDirector	—	39.4K	—
Jul 15, 2026	Heron Elaine JDirector	—	39.4K	—
Jul 15, 2026	Breitmeyer James BDirector	—	8.3K	—
Jul 15, 2026	Watson William MarkDirector	—	39.4K	—
Jul 15, 2026	Wheadon David E.Director	—	39.4K	—
May 21, 2026	Watson William MarkDirector	Purchase at price 0.65 per share.	10K	$6.53K
Apr 22, 2026	Breitmeyer James BDirector	—	78.8K	—
Mar 15, 2026	Berg Edward BGeneral Counsel	—	115K	—
Mar 15, 2026	Grasman Jeroen NicolaasChief Financial Officer	—	227K	—
Mar 15, 2026	Lo StevenChief Executive Officer	—	846.5K	—
Mar 15, 2026	Tucker Sean N.Officer	—	200K	—
Mar 15, 2026	Cummings James F.Officer	—	227K	—
Dec 3, 2025	Lo StevenChief Executive Officer	—	151.4K	—
Nov 16, 2025	Watson William MarkDirector	Purchase at price 0.41 per share.	20K	$8.19K
Nov 16, 2025	Heron Elaine JDirector	Purchase at price 0.39 - 0.40 per share.	40K	$15.92K
Aug 14, 2025	Finney KevinDirector	Purchase at price 0.35 - 0.40 per share.	166.7K	$61.93K
Jul 28, 2025	Watson William MarkDirector	Purchase at price 0.40 per share.	10K	$4.05K
Jun 12, 2025	Finney KevinDirector	Stock Award(Grant) at price 0.00 per share.	6.1K	—
Jun 12, 2025	Heron Elaine JDirector	Stock Award(Grant) at price 0.00 per share.	16K	—
Jun 12, 2025	Finney Michael JosephDirector	Stock Award(Grant) at price 0.00 per share.	16K	—

VXRT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VXRT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vaxart, Inc.

Seasonality · VXRT

Insider Activity · VXRT

Congress Trades · VXRT

Investors Holding VXRT

Investors Holding VXRT

Congress Trades · VXRT

Insider Activity · VXRT

Seasonality · VXRT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vaxart, Inc.

Financial Snapshot

Earnings & Dividends

News